Eli Lilly and Company (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 93,593 Shares of Stock

Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 93,593 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $918.64, for a total value of $85,978,273.52. Following the completion of the transaction, the insider now directly owns 97,153,810 shares in the company, valued at $89,249,376,018.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

• On Friday, July 5th, Lilly Endowment Inc sold 52,369 shares of Eli Lilly and Company stock. The stock was sold at an average price of $915.18, for a total value of $47,927,061.42.
• On Wednesday, July 3rd, Lilly Endowment Inc sold 8,848 shares of Eli Lilly and Company stock. The shares were sold at an average price of $915.31, for a total value of $8,098,662.88.
• On Monday, July 1st, Lilly Endowment Inc sold 58,749 shares of Eli Lilly and Company stock. The shares were sold at an average price of $915.26, for a total value of $53,770,609.74.
• On Friday, June 28th, Lilly Endowment Inc sold 1,441 shares of Eli Lilly and Company stock. The shares were sold at an average price of $915.02, for a total value of $1,318,543.82.
• On Monday, June 24th, Lilly Endowment Inc sold 17,229 shares of Eli Lilly and Company stock. The shares were sold at an average price of $902.38, for a total value of $15,547,105.02.
• On Thursday, June 20th, Lilly Endowment Inc sold 9,671 shares of Eli Lilly and Company stock. The shares were sold at an average price of $902.67, for a total value of $8,729,721.57.
• On Monday, June 17th, Lilly Endowment Inc sold 194,978 shares of Eli Lilly and Company stock. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98.
• On Friday, June 14th, Lilly Endowment Inc sold 15,022 shares of Eli Lilly and Company stock. The shares were sold at an average price of $882.47, for a total value of $13,256,464.34.
• On Monday, June 10th, Lilly Endowment Inc sold 75,510 shares of Eli Lilly and Company stock. The shares were sold at an average price of $860.78, for a total value of $64,997,497.80.
• On Friday, June 7th, Lilly Endowment Inc sold 139,490 shares of Eli Lilly and Company stock. The shares were sold at an average price of $852.29, for a total value of $118,885,932.10.

Eli Lilly and Company Stock Up 1.7 %

Shares of NYSE LLY opened at $933.34 on Wednesday. Eli Lilly and Company has a one year low of $434.34 and a one year high of $935.00. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The business’s fifty day moving average price is $838.34 and its 200-day moving average price is $757.52. The stock has a market capitalization of $887.06 billion, a PE ratio of 137.46, a P/E/G ratio of 1.99 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the prior year, the firm earned $1.62 EPS. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Analyst Ratings Changes

Several research firms have recently commented on LLY. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Morgan Stanley reiterated an “overweight” rating and set a $1,023.00 price target on shares of Eli Lilly and Company in a report on Friday, July 5th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Bank of America reiterated a “buy” rating and set a $1,000.00 price target on shares of Eli Lilly and Company in a report on Monday, June 24th. Finally, The Goldman Sachs Group upped their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $816.78.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc lifted its holdings in Eli Lilly and Company by 1.8% during the 1st quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock worth $573,000 after purchasing an additional 13 shares in the last quarter. Innova Wealth Partners lifted its holdings in Eli Lilly and Company by 1.2% during the 1st quarter. Innova Wealth Partners now owns 1,068 shares of the company’s stock worth $831,000 after purchasing an additional 13 shares in the last quarter. Twin Peaks Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 2.0% during the 1st quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company’s stock worth $559,000 after purchasing an additional 14 shares in the last quarter. Pitti Group Wealth Management LLC increased its stake in Eli Lilly and Company by 0.8% in the 1st quarter. Pitti Group Wealth Management LLC now owns 1,673 shares of the company’s stock worth $1,271,000 after acquiring an additional 14 shares during the last quarter. Finally, Ulland Investment Advisors LLC increased its stake in Eli Lilly and Company by 7.0% in the 1st quarter. Ulland Investment Advisors LLC now owns 214 shares of the company’s stock worth $166,000 after acquiring an additional 14 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.